Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation

Eur Urol. 2015 Jun;67(6):1195-1196. doi: 10.1016/j.eururo.2015.01.015. Epub 2015 Jan 24.

Authors

Siraj M Ali¹, Vincent A Miller¹, Jeffrey S Ross¹, Sumanta K Pal²

Affiliations

¹ Foundation Medicine, Cambridge, MA, USA.
² Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: [email protected].

PMID: 25630452
DOI: 10.1016/j.eururo.2015.01.015

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use
Bridged-Ring Compounds / therapeutic use*
Carcinoma, Transitional Cell / drug therapy
Carcinoma, Transitional Cell / genetics*
Carcinoma, Transitional Cell / pathology
Everolimus / therapeutic use*
Genetic Predisposition to Disease
Humans
Mutation
Neurofibromatosis 2 / genetics*
Taxoids / therapeutic use*
Treatment Outcome
Urinary Bladder / drug effects
Urinary Bladder / pathology*
Urologic Neoplasms / drug therapy*
Urologic Neoplasms / genetics
Urologic Neoplasms / pathology

Substances

Antineoplastic Agents
Bridged-Ring Compounds
Taxoids
taxane
Everolimus